Voya Investment Management LLC increased its stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 3.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,931 shares of the medical research company’s stock after buying an additional 1,662 shares during the quarter. Voya Investment Management LLC owned about 0.11% of PAREXEL International Corporation worth $4,948,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PRXL. Public Employees Retirement System of Ohio grew its stake in PAREXEL International Corporation by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares during the last quarter. Invictus RG bought a new position in PAREXEL International Corporation during the 1st quarter worth $158,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in PAREXEL International Corporation by 10.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after buying an additional 180 shares during the last quarter. Advisor Group Inc. grew its stake in PAREXEL International Corporation by 75.1% during the 2nd quarter. Advisor Group Inc. now owns 2,000 shares of the medical research company’s stock worth $173,000 after buying an additional 858 shares during the last quarter. Finally, BlueCrest Capital Management Ltd bought a new position in PAREXEL International Corporation during the 1st quarter worth $202,000. Hedge funds and other institutional investors own 87.45% of the company’s stock.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) opened at 88.08 on Thursday. The stock has a 50 day moving average price of $87.85 and a 200 day moving average price of $79.27. PAREXEL International Corporation has a one year low of $51.16 and a one year high of $88.10. The firm has a market cap of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77.

PAREXEL International Corporation (NASDAQ:PRXL) last released its earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.94 by $0.08. The company had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same period last year, the firm earned $0.94 EPS. On average, equities research analysts forecast that PAREXEL International Corporation will post $4.06 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Voya Investment Management LLC Buys 1,662 Shares of PAREXEL International Corporation (PRXL)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/voya-investment-management-llc-buys-1662-shares-of-parexel-international-corporation-prxl/1625600.html.

PRXL has been the subject of a number of recent research reports. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Thursday, August 31st. BidaskClub downgraded PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Barclays PLC downgraded PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price objective for the company. in a research note on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and set a $88.10 price objective on shares of PAREXEL International Corporation in a research note on Wednesday, June 21st. Finally, Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research note on Tuesday, June 20th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $75.92.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.